ALCAM and breast cancer: Previous studies have shown that after chemo- and radiotherapy, breast cancer cells are enriched in cells with a CSC-like phenotype characterized by resistance to therapies and high CD44 and CD166 expression, two well-recognized cancer stem cell markers [9,51].